Loughborough, U.K., will be the location for a world-class science and technology park as development of a former AstraZeneca R&D site gets underway. Jayplas acquired the site in 2012 and has confirmed its plans to develop the site into a science park to be known as The Charnwood Biomedical Campus.

The 70-acre campus will provide multi-purpose, specialist laboratories and equipment, stability cabinets, a pilot plant, offices, warehousing and car parking for up to 1,500 vehicles.

The campus is expected to attract tenant businesses from a range of sectors including pharmaceuticals, life sciences, healthcare, new technology, R&D, academia and the public sector, in turn creating opportunities to bring jobs across these sectors back to Loughborough and the East Midlands.

“Charnwood Biomedical Campus will build on the legacy of 43 years of pharmaceutical research and development on the site in Loughborough,” said Dominic Young, director at Charnwood Biomedical Campus, who is leading the site’s redevelopment. “The campus will attract tenant businesses from new start-ups through to established enterprises that are looking to grow and develop in a dedicated and relevant environment. It will be the ideal location for businesses across a range of sectors including pharma, biotech, academia and government organizations.”

“The master plan builds on the existing facilities at the park and will see further investment and expansion as it grows to create a unique environment for businesses to base themselves,” he said.

Charnwood Biomedical Campus is a member of UKSPA (U.K. Science Park Association) and Medilink.